TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical Co., Inc. has completed the acquisition of 254,600 of its own shares, amounting to a total cost of 1,051,793,000 yen, as part of a broader initiative approved by the board of directors in July 2025. This strategic move, executed through open market purchases on the Tokyo Stock Exchange, is part of a larger plan to acquire up to 3 million shares, enhancing the company’s control over its stock and potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a company based in Tosu City, Saga Prefecture, Japan. It operates in the pharmaceutical industry, focusing on the development and production of medicinal products. The company is known for its emphasis on transdermal therapeutic systems and other pharmaceutical solutions.
Average Trading Volume: 194,598
Technical Sentiment Signal: Buy
Current Market Cap: Yen302.4B
See more insights into 4530 stock on TipRanks’ Stock Analysis page.